RSSTopics

Could Palmitoylethanolamide Be an Effective Treatment for Long-COVID-19? Hypothesis and Insights in Potential Mechanisms of Action and Clinical Applications

Could Palmitoylethanolamide Be an Effective Treatment for Long-COVID-19? Hypothesis and Insights in Potential Mechanisms of Action and Clinical Applications

| January 1, 2022

by Loredana Raciti, MD, PhD; Francesca Antonia Arcadi, MD, PhD; and Rocco Salvatore Calabrò, MD, PhD Drs. Raciti, Arcadi, and Calabrò are with IRCCS Centro Neurolesi “Bonino Pulejo” in Messina, Italy. Funding: No funding was provided for this study.   Disclosures: The authors have no conflicts of interest relevant to the content of this article.  Innov […]

Continue Reading

Making Sense of the Matrix: A Qualitative Assessment and Commentary on Connecting Psychiatric Symptom Scale Items to the Research Domain Criteria (RDoC)

Making Sense of the Matrix: A Qualitative Assessment and Commentary on Connecting Psychiatric Symptom Scale Items to the Research Domain Criteria (RDoC)

| January 1, 2022

by Leslie Citrome, MD, MPH; Anissa Abi-Dargham, MD; Robert M. Bilder, PhD; Ruth A. Duffy, PhD; Boadie W. Dunlop, MD; Philip D. Harvey, PhD; Diego A. Pizzagalli, PhD; Carol A. Tamminga, MD; Roger S. McIntyre, MD; and John M. Kane, MD Dr. Citrome is with New York Medical College in Valhalla, New York. Dr. Abi-Dargham is with […]

Continue Reading

Selective Serotonin Reuptake Inhibitors (SSRIs) and Their Effect on Patient Aggression in Adult Patients in a State Psychiatric Facility: A Retrospective Analysis

Selective Serotonin Reuptake Inhibitors (SSRIs) and Their Effect on Patient Aggression in Adult Patients in a State Psychiatric Facility: A Retrospective Analysis

| January 1, 2022

by Carolyn O’Donnell, PharmD; Tammie Lee Demler, PharmD, MBA, BCGP, BCPP; and Eileen Trigoboff, RN, PMHCNS-BC, DNS, DABFN;  Drs. O’Donnell, Demler, and Trigoboff are with the State University of New York at Buffalo School of Pharmacy and Pharmaceutical Sciences, Department of Pharmacy Practice in Buffalo, New York. Drs. O’Donnell and Demler are with the New York State […]

Continue Reading

Pimavanserin in the Treatment of Parkinson’s Disease Psychosis: Meta-analysis and Meta-regression of Randomized Clinical Trials

Pimavanserin in the Treatment of Parkinson’s Disease Psychosis: Meta-analysis and Meta-regression of Randomized Clinical Trials

| January 1, 2022

by Zeeshan Mansuri, MD, MPH; Abhishek Reddy, MD; Ramu Vadukapuram, MD; Chintan Trivedi, MD, MPH; and Amy Amara, MD, PhD  Dr. Mansuri is with the Department of Psychiatry, Boston Children’s Hospital/Harvard Medical School in Boston, Massachusetts. Dr. Reddy is with the Department of Psychiatry, Virginia Tech Carilion School of Medicine in Roanoke, Virginia. Dr. Vadukapuram is with […]

Continue Reading

Using Artificial Intelligence-based Methods to Address the Placebo Response in Clinical Trials

Using Artificial Intelligence-based Methods to Address the Placebo Response in Clinical Trials

| January 1, 2022

by Erica A. Smith, PhD; William P. Horan, PhD; Dominique Demolle, PhD; Peter Schueler, MD; Dong-Jing Fu, MD, PhD; Ariana E. Anderson, PhD; Joseph Geraci, MSc, PhD; Florence Butlen-Ducuing, MD, PhD; Jasmine Link, MS; Ni A. Khin, MD; Robert Morlock, PhD; and Larry D. Alphs, MD, PhD Drs. Smith and Demolle are with Cognivia in Mont St. […]

Continue Reading

Letter to the Editor: Elevated Level of CXCL13 in Nonenhancing Diffuse Primary Lymphoma of the Brainstem

Letter to the Editor: Elevated Level of CXCL13 in Nonenhancing Diffuse Primary Lymphoma of the Brainstem

| October 1, 2021

Innov Clin Neurosci. 2021;18(10–12):8. Dear Editor: Primary central nervous system (CNS) lymphoma (pCNL) is a rare neoplasia predominantly of the brain. Histologically, most of these neoplasias are diffuse large B-cell lymphomas.1 Although the exact diagnosis requires pathological confirmation, magnetic resonance imaging (MRI) often shows characteristic results, such as enhancement.2 However, nonenhancing pCNL have been described […]

Continue Reading